Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 1, 2025AntibodiesOpen Access

Serum Factors in Primary Podocytopathies

View Full Paper
Ask AI
Bookmark
Share

Authors

EFEdward J. FilipponeJFJohn L. Farber

Discussion

Loading...

Member takes

Overview

This research discusses antibody and non-antibody circulating factors in primary podocytopathies, suggesting therapeutic avenues.

Key Points

  • Antibody pathogenesis is supported by the presence of anti-nephrin antibodies in many patients with primary podocytopathies.
  • Significant circulating factors like cardiotrophin-like cytokine 1 are implicated in diseases such as minimal change disease and focal segmental glomerulosclerosis.
  • The use of immunosuppressive agents, like rituximab, has shown effectiveness in treating podocytopathies, further highlighting antibody involvement.
  • High-resolution microscopy reveals immunoglobulin deposits that may aid in identifying the underlying mechanisms and potential treatments.

Cite This Study

Filippone et al. (2025) studied this question.

synapsesocial.com/papers/68dd89defe798ba2fc497cf6https://doi.org/10.3390/antib14040082
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A New Hope for Treating Podocytopathies — Emerging Role of Anti-Nephrin Antibody2026
  2. 2Autoantibodies targeting CRB2 and Nephrin correlate with extrafollicular B cells in idiopathic podocytopathies2025
  3. 3The Influence of Anti-C3aR and Anti-C5aR Antibody Levels on the Course of Specific Glomerulonephritis Types2025
  4. 4Anti-nephrin antibodies in minimal change disease: Case report series2025
  5. 5Focal Segmental Glomerulosclerosis: Comprehensive Review and Exploration of the Dual Potential of Cyclodextrins in Therapeutic Optimization2025